What is Combinostics?
Combinostics specializes in artificial intelligence technology designed to enhance the early diagnosis and management of neurological disorders. Their core offering, cNeuro, is a sophisticated platform that integrates cMRI and cDSI applications. This comprehensive solution empowers clinicians by providing a unified view of patient data, combining imaging insights with clinical information to facilitate more informed decision-making. The company's target market includes healthcare professionals such as neurologists and radiologists who require advanced diagnostic and monitoring tools for neurodegenerative diseases. By employing AI and cloud-based infrastructure, Combinostics aims to improve communication and collaboration among medical teams, ultimately leading to better patient outcomes.
How much funding has Combinostics raised?
Combinostics has raised a total of $4.3M across 1 funding round:
Series A
$4.3M
Series A (2019): $4.3M with participation from Industrifonden and NordicNinja VC
Key Investors in Combinostics
Industrifonden
Industrifonden is a Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies and science. The fund focuses on areas such as deep tech, life sciences, and transformative tech, partnering with passionate founders to bring their ideas to life.
NordicNinja VC
NordicNinja VC is a venture capital firm that typically invests in early-stage technology companies, with a focus on deep tech and digital transformation.
What's next for Combinostics?
The substantial enterprise-level funding received by Combinostics positions the company for significant scaling and further development of its AI-powered diagnostic solutions. This strategic investment is likely to fuel advancements in their cNeuro platform, potentially expanding its capabilities and market reach. Future growth may involve deeper integration into clinical workflows, further research into AI algorithms for neurological conditions, and strategic partnerships within the healthcare technology sector. The company's focus on early diagnosis and management of neurological disorders aligns with a growing global demand for innovative healthcare solutions, suggesting a strong trajectory for future expansion and impact.
See full Combinostics company page
